samatasvir Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.   Wikipedia

Chemistry

  • SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2nc3cc(ccc3[nH]2)c4csc5c(csc45)c6ccc(cc6)c7c[nH]c(n7)[C@@H]8CCCN8C(=O)[C@H](NC(=O)OC)c9ccccc9
  • InChIKey: ATOLIHZIXHZSBA-BTSKBWHGSA-N
  • Mol. Mass: 885.08
  • ALogP: 9.37
  • ChEMBL Molecule:
    samatasvir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

idx18719 | idx719 | samatasvir

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Hepatitis C (Phase 1)

Hepatitis C, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue